Drug Trial Radar · NCT07694089
Steroid Avoidance, Dexamethasone, and RAGE Inhibition for Perioperative Cerebral Edema Management in High-Grade Gliomas
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Aug 1, 2029
Study completion Aug 1, 2029
Sponsor
- Lead sponsor
- Akshitkumar MIstryAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Cantex Pharmaceuticals Inc.; James Graham Brown Cancer Center
- First posted
- Jul 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Supportive care
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to learn whether two alternatives to standard steroid treatment can safely control swelling around a brain tumor after surgery. The study will compare three approaches by placing participants in one of three study groups: standard dexamethasone (a steroid), no routine steroid treatment, and azeliragon, a study drug that may reduce brain swelling through a different pathway. Researchers want to determine whether these alternatives can control swelling while reducing some of the side effects associated with steroid use. Participants in this study will be randomly assigned to one of three study groups. Participants will undergo their planned brain tumor surgery and receive the treatment assigned to their group. Study procedures are the same as their routine care and include physical and neurological examinations, blood tests, MRI scans, review of medical records, and collection of tumor tissue removed during surgery (optional). Most study visits will occur during routine medical care. Participants will be followed for approximately 24 months after surgery.
Conditions
- High-grade Gliomas (HGG)
Interventions
DexamethasoneDrug
Potent FDA-approved corticosteroid
AzeliragonDrug
orally bioavailable inhibitor of the receptor for advanced glycation endproducts (RAGE)
Primary outcomes
What the sponsor says the trial is designed to measure.
- change in peritumoral edema between the preoperative and postoperative periodTime frame: before the start of adjuvant chemo radiation (up to 6 weeks)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
UofL Health Brown Cancer Center; University of Louisville Hospital
Louisville, Kentucky
UofL Health Jewish Hospital
Louisville, Kentucky
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.